Kyoto University

Sidonia Fagarasan

Tasuku Honjo

Fumihiko Matsuda

Yasushi Okuno

Kenji Chamoto

The present invention provides markers for judging the efficacy of therapy with a PD-1 signal inhibitor before or at an early stage of the therapy. As biomarkers for predicting or judging the efficacy of therapy with a PD-1 signal inhibitor, surrogate indicators of metabolic changes relating to mitochondrial activity in T cells and/or T cell activation in a subject are used. As such indicators, intestinal flora-related metabolites in the serum or plasma, energy metabolism-related metabolites in the serum or plasma, amino acid metabolism-related metabolites and/or derivatives thereof in the serum of plasma, oxygen consumption rate and/or ATP turnover in peripheral blood CD8cells, amino acids in T cells, and T-bet in peripheral blood CD8cells may be used.

Growing community of inventors

Saitama, Japan

Sidonia Fagarasan